FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 357:2248-2261 November 29, 2007 Number 22 Next

John Kjekshus, M.D., Ph.D., Eduard Apetrei, M.D., Ph.D., Vivencio Barrios, M.D., Ph.D., Michael Böhm, M.D., Ph.D., John G.F. Cleland, M.D., Jan H. Cornel, M.D., Ph.D., Peter Dunselman, M.D., Ph.D., Cândida Fonseca, M.D., Assen Goudev, M.D., Ph.D., Peer Grande, M.D., Ph.D., Lars Gullestad, M.D., Ph.D., Åke Hjalmarson, M.D., Ph.D., Jaromir Hradec, M.D., Ph.D., András Jánosi, M.D., D.Sc., Gabriel Kamensk, M.D., Ph.D., Michel Komajda, M.D., Jerzy Korewicki, M.D., Ph.D., Timo Kuusi, M.D., Ph.D., François Mach, M.D., Vyacheslav Mareev, M.D., Ph.D., John J.V. McMurray, M.D., Naresh Ranjith, M.D., Maria Schaufelberger, M.D., Ph.D., Johan Vanhaecke, M.D., Ph.D., Dirk J. van Veldhuisen, M.D., Ph.D., Finn Waagstein, M.D., Ph.D., Hans Wedel, Ph.D., John Wikstrand, M.D., Ph.D., for the CORONA Group

	Full Text PDF PDA Full Text PowerPoint Slide Set Editorial by Masoudi, F. A. Letters Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear PubMed Citation

ABSTRACT

Background Patients with systolic heart failure have generally been excluded from statin trials. Acute coronary events are uncommon in this population, and statins have theoretical risks in these patients.

Methods A total of 5011 patients at least 60 years of age with New York Heart Association class II, III, or IV ischemic, systolic heart failure were randomly assigned to receive 10 mg of rosuvastatin or placebo per day. The primary composite outcome was death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke. Secondary outcomes included death from any cause, any coronary event, death from cardiovascular causes, and the number of hospitalizations.

Results As compared with the placebo group, patients in the rosuvastatin group had decreased levels of low-density lipoprotein cholesterol (difference between groups, 45.0%; P<0.001) and of high-sensitivity C-reactive protein (difference between groups, 37.1%; P<0.001). During a median follow-up of 32.8 months, the primary outcome occurred in 692 patients in the rosuvastatin group and 732 in the placebo group (hazard ratio, 0.92; 95% confidence interval [CI], 0.83 to 1.02; P=0.12), and 728 patients and 759 patients, respectively, died (hazard ratio, 0.95; 95% CI, 0.86 to 1.05; P=0.31). There were no significant differences between the two groups in the coronary outcome or death from cardiovascular causes. In a prespecified secondary analysis, there were fewer hospitalizations for cardiovascular causes in the rosuvastatin group (2193) than in the placebo group (2564) (P<0.001). No excessive episodes of muscle-related or other adverse events occurred in the rosuvastatin group.

Conclusions Rosuvastatin did not reduce the primary outcome or the number of deaths from any cause in older patients with systolic heart failure, although the drug did reduce the number of cardiovascular hospitalizations. The drug did not cause safety problems. (ClinicalTrials.gov number, NCT00206310 [ClinicalTrials.gov] .)

Source Information

Affiliations for authors are listed in the Appendix.

This article (10.1056/NEJMoa0706201) was published at www.nejm.org on November 5, 2007.

Address reprint requests to Dr. Kjekshus at the Department of Cardiology, University of Oslo, Rikshospitalet University Hospital, Oslo, Norway, or at john.kjekshus{at}medisin.uio.no.

Full Text of this Article

Related Letters:

Rosuvastatin in Older Patients with Systolic Heart Failure
Florkowski C. M., Molyneux S. L., George P. M., Kjekshus J., McMurray J. J.V., Wikstrand J.
Extract | Full Text | PDF  
N Engl J Med 2008; 358:1301, Mar 20, 2008. Correspondence

This article has been cited by other articles:

• de Bie, M. K., van Dam, B., Gaasbeek, A., van Buren, M., van Erven, L., Bax, J. J., Schalij, M. J., Rabelink, T. J., Jukema, J. W. (2009). The current status of interventions aiming at reducing sudden cardiac death in dialysis patients. Eur Heart J 30: 1559-1564 [Abstract] [Full Text]  
• van Veldhuisen, D. J., Cohen-Solal, A., Bohm, M., Anker, S. D., Babalis, D., Roughton, M., Coats, A. J.S., Poole-Wilson, P. A., Flather, M. D., SENIORS Investigators, (2009). Beta-blockade with nebivolol in elderly heart failure patients with impaired and preserved left ventricular ejection fraction: Data From SENIORS (Study of Effects of Nebivolol Intervention on Outcomes and Rehospitalization in Seniors With Heart Failure).. J Am Coll Cardiol 53: 2150-2158 [Abstract] [Full Text]  
• Cleland, J. G.F., Coletta, A. P., Clark, A. L., Cullington, D. (2009). Clinical trials update from the American College of Cardiology 2009: ADMIRE-HF, PRIMA, STICH, REVERSE, IRIS, partial ventricular support, FIX-HF-5, vagal stimulation, REVIVAL-3, pre-RELAX-AHF, ACTIVE-A, HF-ACTION, JUPITER, AURORA, and OMEGA. Eur J Heart Fail 11: 622-630 [Abstract] [Full Text]  
• Ben-Yehuda, O., DeMaria, A. N. (2009). Statins in Rheumatic Heart Disease: Taking the Bite Out?. J Am Coll Cardiol 53: 1880-1882 [Full Text]  
• Vivo, R. P., Krim, S. R., Cevik, C., Witteles, R. M. (2009). Heart failure in hispanics.. J Am Coll Cardiol 53: 1167-1175 [Abstract] [Full Text]  
• Strippoli, G. F.M., Craig, J. C. (2009). Sunset for Statins after AURORA?. NEJM 360: 1455-1457 [Full Text]  
• Fellstrom, B. C., Jardine, A. G., Schmieder, R. E., Holdaas, H., Bannister, K., Beutler, J., Chae, D.-W., Chevaile, A., Cobbe, S. M., Gronhagen-Riska, C., De Lima, J. J., Lins, R., Mayer, G., McMahon, A. W., Parving, H.-H., Remuzzi, G., Samuelsson, O., Sonkodi, S., Sci., D., Suleymanlar, G., Tsakiris, D., Tesar, V., Todorov, V., Wiecek, A., Wuthrich, R. P., Gottlow, M., Johnsson, E., Zannad, F., the AURORA Study Group, (2009). Rosuvastatin and Cardiovascular Events in Patients Undergoing Hemodialysis. NEJM 360: 1395-1407 [Abstract] [Full Text]  
• Dargie, H.J. (2009). Current controversies in drug use. Eur J Heart Fail Suppl 8: i15-i20 [Full Text]  
• Laufs, U, Custodis, F, Bohm, M (2009). Who does not need a statin: too late in end-stage renal disease or heart failure?. Postgrad. Med. J. 85: 187-189 [Abstract] [Full Text]  
• Schmechel, A., Grimm, M., El-Armouche, A., Hoppner, G., Schwoerer, A. P., Ehmke, H., Eschenhagen, T. (2009). Treatment with atorvastatin partially protects the rat heart from harmful catecholamine effects. Cardiovasc Res 82: 100-106 [Abstract] [Full Text]  
• Konstam, M. A. (2009). Antithrombotic Therapy in Heart Failure: WATCHful Wondering. Circulation 119: 1559-1561 [Full Text]  
• Cleland, J. G.F., Cullington, D. (2009). Digoxin: Quo Vadis?. Circ Heart Fail 2: 81-85 [Full Text]  
• Baumhakel, M., Muller, U., Bohm, M. (2009). Influence of gender of physicians and patients on guideline-recommended treatment of chronic heart failure in a cross-sectional study. Eur J Heart Fail 11: 299-303 [Abstract] [Full Text]  
• Wedel, H., McMurray, J. J.V., Lindberg, M., Wikstrand, J., Cleland, J. G.F., Cornel, J. H., Dunselman, P., Hjalmarson, A., Kjekshus, J., Komajda, M., Kuusi, T., Vanhaecke, J., Waagstein, F., on behalf of the CORONA Study Group, (2009). Predictors of fatal and non-fatal outcomes in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA): incremental value of apolipoprotein A-1, high-sensitivity C-reactive peptide and N-terminal pro B-type natriuretic peptide. Eur J Heart Fail 11: 281-291 [Abstract] [Full Text]  
• Landmesser, U., Wollert, K. C., Drexler, H. (2009). Potential novel pharmacological therapies for myocardial remodelling. Cardiovasc Res 81: 519-527 [Abstract] [Full Text]  
• Hori, M., Nishida, K. (2009). Oxidative stress and left ventricular remodelling after myocardial infarction. Cardiovasc Res 81: 457-464 [Abstract] [Full Text]  
• Howlett, J. G. (2009). Performance feedback a common thread in the process to provide optimal heart failure care.. J Am Coll Cardiol 53: 423-425 [Full Text]  
• Nicolini, F., Gherli, T. (2009). Alternatives to transplantation in the surgical therapy for heart failure. Eur. J. Cardiothorac. Surg. 35: 214-228 [Abstract] [Full Text]  
• Scirica, B. M., Cannon, C. P., Sabatine, M. S., Jarolim, P., Sloane, S., Rifai, N., Braunwald, E., Morrow, D. A., for the PROVE IT-TIMI 22 Investigators, (2009). Concentrations of C-Reactive Protein and B-Type Natriuretic Peptide 30 Days after Acute Coronary Syndromes Independently Predict Hospitalization for Heart Failure and Cardiovascular Death. Clin. Chem. 55: 265-273 [Abstract] [Full Text]  
• Bolli, R., Dawn, B. (2009). The Cornucopia of "Pleiotropic" Actions of Statins: Myogenesis As a New Mechanism for Statin-Induced Benefits?. Circ. Res. 104: 144-146 [Full Text]  
• Suzuki, G., Iyer, V., Cimato, T., Canty, J. M. Jr (2009). Pravastatin Improves Function in Hibernating Myocardium by Mobilizing CD133+ and cKit+ Bone Marrow Progenitor Cells and Promoting Myocytes to Reenter the Growth Phase of the Cardiac Cell Cycle. Circ. Res. 104: 255-264 [Abstract] [Full Text]  
• Pfisterer, M., Buser, P., Rickli, H., Gutmann, M., Erne, P., Rickenbacher, P., Vuillomenet, A., Jeker, U., Dubach, P., Beer, H., Yoon, S.-I., Suter, T., Osterhues, H. H., Schieber, M. M., Hilti, P., Schindler, R., Brunner-La Rocca, H.-P., for the TIME-CHF Investigators, (2009). BNP-Guided vs Symptom-Guided Heart Failure Therapy: The Trial of Intensified vs Standard Medical Therapy in Elderly Patients With Congestive Heart Failure (TIME-CHF) Randomized Trial. JAMA 301: 383-392 [Abstract] [Full Text]  
• Ezekowitz, J. A., Kaul, P., Bakal, J. A., Armstrong, P. W., Welsh, R. C., McAlister, F. A. (2009). Declining in-hospital mortality and increasing heart failure incidence in elderly patients with first myocardial infarction.. J Am Coll Cardiol 53: 13-20 [Abstract] [Full Text]  
• Liang, C.-s., Delehanty, J. D. (2009). Increasing post-myocardial infarction heart failure incidence in elderly patients a call for action.. J Am Coll Cardiol 53: 21-23 [Full Text]  
• Rabaeus, M. (2008). JUPITER may yet change practice. BMJ 337: a2921-a2921 [Full Text]  
• Leclercq, C., Mabo, P., Trochu, J. N. (2008). Cardiac Resynchronization for Asymptomatic or Mildly Symptomatic Heart Failure: A Bridge Too Far?. J Am Coll Cardiol 52: 1844-1846 [Full Text]  
• Jukema, J W., Bergheanu, S. C (2008). Statins: established indications and controversial subgroups. Heart 94: 1656-1662 [Full Text]  
• Coletta, A. P., Cullington, D., Clark, A. L., Cleland, J. G.F. (2008). Clinical trials update from European Society of Cardiology meeting 2008: TIME-CHF, BACH, BEAUTIFUL, GISSI-HF, and HOME-HF. Eur J Heart Fail 10: 1264-1267 [Abstract] [Full Text]  
• Donner-Banzhoff, N., Sonnichsen, A. (2008). Statins and primary prevention of cardiovascular events. BMJ 337: a2576-a2576 [Full Text]  
• Tang, W.H. W., Francis, G. S. (2008). The Year in Heart Failure. J Am Coll Cardiol 52: 1671-1678 [Full Text]  
• Pasquali, S. K., Li, J. S. (2008). Prevention of Future Cardiovascular Disease in High-Risk Pediatric Patients: A Role for Lipid Lowering Therapy?. Circ Cardiovasc Qual Outcomes 1: 131-133 [Full Text]  
• Wong, L. S.M., de Boer, R. A., Samani, N. J., van Veldhuisen, D. J., van der Harst, P. (2008). Telomere biology in heart failure. Eur J Heart Fail 10: 1049-1056 [Abstract] [Full Text]  
• Molyneux, S. L., Florkowski, C. M., George, P. M., Pilbrow, A. P., Frampton, C. M., Lever, M., Richards, A. M. (2008). Coenzyme Q10: An Independent Predictor of Mortality in Chronic Heart Failure. J Am Coll Cardiol 52: 1435-1441 [Abstract] [Full Text]  
• Athyros, V. G., Kakafika, A. I., Tziomalos, K., Karagiannis, A., Mikhailidis, D. P. (2008). CORONA, Statins, and Heart Failure: Who Lost the Crown?. ANGIOLOGY 59: 641-642  
• Authors/Task Force Members, , Dickstein, K., Cohen-Solal, A., Filippatos, G., McMurray, J. J.V., Ponikowski, P., Poole-Wilson, P. A., Stromberg, A., van Veldhuisen, D. J., Atar, D., Hoes, A. W., Keren, A., Mebazaa, A., Nieminen, M., Priori, S. G., Swedberg, K., ESC Committee for Practice Guidelines (CPG), , Vahanian, A., Camm, J., De Caterina, R., Dean, V., Dickstein, K., Filippatos, G., Funck-Brentano, C., Hellemans, I., Kristensen, S. D., McGregor, K., Sechtem, U., Silber, S., Tendera, M., Widimsky, P., Zamorano, J. L., Document Reviewers, , Tendera, M., Auricchio, A., Bax, J., Bohm, M., Corra, U., della Bella, P., Elliott, P. M., Follath, F., Gheorghiade, M., Hasin, Y., Hernborg, A., Jaarsma, T., Komajda, M., Kornowski, R., Piepoli, M., Prendergast, B., Tavazzi, L., Vachiery, J.-L., Verheugt, F. W. A., Zamorano, J. L., Zannad, F. (2008). ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur Heart J 29: 2388-2442 [Full Text]  
• Dickstein, K., Cohen-Solal, A., Filippatos, G., McMurray, J. J.V., Ponikowski, P., Poole-Wilson, P. A., Stromberg, A., van Veldhuisen, D. J., Atar, D., Hoes, A. W., Keren, A., Mebazaa, A., Nieminen, M., Priori, S. G., Swedberg, K. (2008). ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur J Heart Fail 10: 933-989 [Full Text]  
• Cleland, J. G.F., Squire, I., Ng, L. (2008). Interpretation of Amino-Terminal Pro-Brain Natriuretic Peptide Levels in the HPS and the CORONA Study. J Am Coll Cardiol 52: 1104-1105 [Full Text]  
• Kostapanos, M. S., Milionis, H. J., Elisaf, M. S. (2008). An Overview of the Extra-Lipid Effects of Rosuvastatin. J CARDIOVASC PHARMACOL THER 13: 157-174 [Abstract]  
• Laufs, U, Custodis, F, Bohm, M (2008). Who does not need a statin: too late in end-stage renal disease or heart failure?. Heart 94: 1138-1140 [Abstract] [Full Text]  
• Filippatos, T. D., Mikhailidis, D. P. (2008). Statins and Heart Failure. ANGIOLOGY 59: 58S-61S [Abstract]  
• Efthimiadis, A. (2008). Rosuvastatin and Cardiovascular Disease: Did the Strongest Statin Hold the Initial Promises?. ANGIOLOGY 59: 62S-64S [Abstract]  
• DAVIDSON, M. H. (2008). Is ezetimibe/simvastatin no better than simvastatin alone? Lessons learned and clinical implications. Cleveland Clinic Journal of Medicine 75: 479-496 [Full Text]  
• Bhavnani, S. P., Coleman, C. I., White, C. M., Clyne, C. A., Yarlagadda, R., Guertin, D., Kluger, J. (2008). Association between statin therapy and reductions in atrial fibrillation or flutter and inappropriate shock therapy. Europace 10: 854-859 [Abstract] [Full Text]  
• Werner, C. M., Bohm, M. (2008). Review: The therapeutic role of RAS blockade in chronic heart failure. Ther Adv Cardiovasc Dis 2: 167-177 [Abstract]  
• Peterson, E. D., Wang, T. Y. (2008). The Great Debate of 2008--How Low to Go in Preventive Cardiology?. JAMA 299: 1718-1720 [Full Text]  
• Torabi, A., Cleland, J. G.F., Khan, N. K., Loh, P. H., Clark, A. L., Alamgir, F., Caplin, J. L., Rigby, A. S., Goode, K. (2008). The timing of development and subsequent clinical course of heart failure after a myocardial infarction. Eur Heart J 29: 859-870 [Abstract] [Full Text]  
• Florkowski, C. M., Molyneux, S. L., George, P. M., Kjekshus, J., McMurray, J. J.V., Wikstrand, J. (2008). Rosuvastatin in Older Patients with Systolic Heart Failure. NEJM 358: 1301-1301 [Full Text]  
• Athyros, V. G., Kakafika, A. I., Tziomalos, K., Karagiannis, A., Mikhailidis, D. P. (2008). CORONA, Statins, and Heart Failure: Who Lost the Crown?. ANGIOLOGY 59: 5-8  
• Levy, W. C. (2008). Can B-type natriuretic peptides replace heart failure risk models?. Eur J Heart Fail 10: 224-225 [Full Text]  
• Ramasubbu, K., Estep, J., White, D. L., Deswal, A., Mann, D. L. (2008). Experimental and clinical basis for the use of statins in patients with ischemic and nonischemic cardiomyopathy.. J Am Coll Cardiol 51: 415-426 [Abstract] [Full Text]  
• Swedberg, K. (2008). How to publish in European Journal of Heart Failure -- what do we want?. Eur J Heart Fail 10: 1-2 [Full Text]  
• Cleland, J. G.F., Coletta, A. P., Abdellah, A. T., Cullington, D., Clark, A. L., Rigby, A. S. (2008). Clinical trials update from the American Heart Association 2007: CORONA, RethinQ, MASCOT, AF-CHF, HART, MASTER, POISE and stem cell therapy. Eur J Heart Fail 10: 102-108 [Abstract] [Full Text]  
• Masoudi, F. A. (2007). Statins for Ischemic Systolic Heart Failure. NEJM 357: 2301-2304 [Full Text]  
• (2007). Can Statins Benefit Elderly Patients with Ischemic Heart Failure?. JWatch General 2007: 8-8 [Full Text]